TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05110001
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.
Study: NCT05110001
Drug: Natamycin
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
Study: NCT05110001
Drug: Rose Bengal
Normalized name: Rose bengal
DrugBank: Rose bengal (DB11182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.
Study: NCT05944211
Drug: Hetrombopag Olamine
Normalized name: Eltrombopag Olamine
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will initiate treatment with 7.5 mg hetrombopag once a day, starting orally 24 hours after the end of chemotherapy. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts once every two weeks, and maximum dose should not exceed 15 mg daily. Subjects whose platelet count \<25×109/L for 2 weeks, the hetrombopag dose will be increased by 2.5mg. If subjects whose platelet count ≥100×109/L or who had received hetrombopag for 28 days, hetrombopag can be stopped. Hetrombopag Olamine is sponsored by Jiangsu Hengrui Pharmaceuticals Co., Ltd.~Emergency treatment: When the platelet count was less than 20×109/L, platelet transfusion was given according to the evaluation of the investigator.
Study: NCT05655312
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For all combination-therapy cohorts, 480 mg nivolumab will be administered every 4 weeks as an IV infusion.
Study: NCT05509894
Drug: Ngenla
Normalized name: Ngenla
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: As provided in real world practice
Study: NCT05488171
Drug: Methylone
Normalized name: Methylone
DrugBank: Methylone (DB19192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 200 mg of methylone.
Study: NCT05488171
Drug: 3,4-methylenedioxymethamphetamine
Normalized name: 3,4-Methylenedioxymethamphetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 100 mg of MDMA.
Study: NCT06479304
Drug: Hydroxychloroquine Oral Tablet
Normalized name: hydroxychloroquine Oral Tablet
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
Study: NCT06181591
Drug: Mirabegron 50 MG
Normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron (IP: Hibero) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). It is used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. Through a 8 weeks clinical trial, it aims to evaluate the efficacy and safety of Hibero (Mirabegron), especially in maximum voided volume.
Study: NCT06181591
Drug: Oxybutynin Chloride 5 MG
Normalized name: oxybutynin chloride 5 MG
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin has been used to treat overactive bladder (OAB). The subject will take 5 mg of Ditropan (Oxybutynin Chloride) twice a day, in total of 10 mg for 8 weeks.
Study: NCT06013423
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive IV or PO
Study: NCT06013423
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive IV
Study: NCT06479304
Drug: Prednisone tablet
Normalized name: Prednisone Tablets
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone is given at the dose of 1mg/kg every morning after meals for 2 weeks ( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, prednisone will be given at the dose for 2 more weeks ), then tapering off.
Study: NCT06013423
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Receive IV
Study: NCT06013423
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Receive IV
Study: NCT06306989
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be categorized into high-risk and intermediate-risk groups based on risk factors for CMV infection.Initiate letemovir prophylaxis on day +1 in high-risk patients and on days +7 to +14 in non-high-risk patients.(240 mg, qd in patients with concomitant cyclosporine; 480 mg, qd in patients with concomitant tacrolimus) to +100 days. For patients with comorbid GVHD who require intensive immunosuppression, consider extending the regimen to +200 days.
Study: NCT05009927
Drug: Imatinib tablets
Normalized name: Imatinib Tablets
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib interruption
Study: NCT00429923
Drug: Difluprednate
Normalized name: Difluprednate
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04971109
Drug: TPOXX
Normalized name: Tpoxx
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study is based on Animal Regulatory Rule
Study: NCT05780073
Drug: Dasatinib 70 mg
Normalized name: dasatinib 70 MG
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind
Study: NCT06086275
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At each visit, the participant will receive a single dose of buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO.
Study: NCT05475171
Drug: Lorigerlimab
Normalized name: Lorigerlimab
DrugBank: Lorigerlimab (DB18942)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by vein (IV)
Study: NCT05872204
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg tablet twice daily
Study: NCT06136195
Drug: Mavoglurant
Normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
Study: NCT05872204
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg tablet once daily
Study: NCT04385264
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
Study: NCT04385264
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
Study: NCT04965090
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
Study: NCT04965090
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh \<80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
Study: NCT04685421
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
Study: NCT05085873
Drug: Sodium Oxybate injection
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Induction dosage : 60 mg/kg by direct intravenous injection.~* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.~* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.~Sedation maintained until patient death.
Study: NCT05085873
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).~* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.~* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).~Sedation maintained until patient death.
Study: NCT05053893
Drug: Roxadustat;Sacubitril Valsartan Sodium Tablets;
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Select the appropriate dose according to the patient's situation
Study: NCT04986423
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg PO QD
Study: NCT05681299
Drug: growth hormone and lirglutide
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
Study: NCT05681299
Drug: growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
Study: NCT05681299
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
Study: NCT05990465
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirtobrutinib will be administered at 200 mg/day orally starting at least 14 days prior to apheresis as bridging until the start of lymphodepletion and restarted between day 28-120 for up to one year as maintenance post cell infusion.
Study: NCT05492695
Drug: Galcanezumab
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
Study: NCT03878953
Drug: rhPTH(1-84)
Normalized name: rhPTH(1-84)
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; \[mg/dL\] = serum calcium \[mg/dL\] +0.8\*\[4-serum albumin (g/dL)\]) is \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is \>2.97 mmol/L (\>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
Study: NCT05600660
Drug: Orelabrutinib
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib will be given as 150 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6 cycles during induction treatment.~Daily Orelabrutinb will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
Study: NCT05600660
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy.
Study: NCT05637879
Drug: Glecaprevir/pibrentasvir
Normalized name: GLECAPREVIR/PIBRENTASVIR
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection
Study: NCT06557018
Drug: liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: liposomal bupivacaine group
Study: NCT06422507
Drug: 8 mg aflibercept (BAY 86-5321) (High Dose)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.
Study: NCT06422507
Drug: 2 mg aflibercept (EYLEA, BAY 86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study fellow eye treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye.
Study: NCT06075667
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06382831
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Opioid free anesthesia
Study: NCT05515536
Drug: Vatiquinone
Normalized name: Vatiquinone
DrugBank: Vatiquinone (DB11917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Study: NCT06079775
Drug: Xeruborbactam Oral Prodrug
Normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Fostroxacitabine bralpamide (DB18090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT06079775
Drug: Ceftibuten
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental
Study: NCT06079775
Drug: Ceftibuten Placebo
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT05089279
Drug: CKD-349
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05640479
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
Study: NCT05640479
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
Study: NCT05882045
Drug: Retatrutide
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06538116
Drug: Mevidalen
Normalized name: Mevidalen
DrugBank: Mevidalen (DB19034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06337630
Drug: PLX038 + Tuvusertib
Normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation will be conducted on the grid defined by the 4 doses of PLX038 (800 mg/m², 1000 mg/m², 1300 mg/m² and 1700 mg/m² IV every 21 days D1=D22) and 3 doses of Tuvusertib (90 mg, 130 mg and 180 mg QD for 10 days from D3, D3-12). Premedication with anti-emetic agents is not required prior to the initial infusion, but may be used for an individual patient, as needed.~All included patients will receive PLX038 + Tuvusertib until progression of disease, unacceptable toxicity, patient withdrawal of consent, investigator decision, lost to follow-up, death, patient non-compliance, or study termination by Sponsor.
Study: NCT05176080
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib orally, daily or every other day
Study: NCT05176080
Drug: SHR6390
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390 orally, daily for 3 weeks followed by 1 week off
Study: NCT05176080
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant
Study: NCT04088942
Drug: Low-intensity smoking cessation intervention
Normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
Study: NCT05639751
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered by intravenous infusion
Study: NCT05219617
Drug: Carisbamate
Normalized name: carisbamate
DrugBank: Carisbamate (DB12338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).
Study: NCT05614765
Drug: Statin+Ezetimibe compound
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Crezet Tablet, Litorvazet Tablet
Study: NCT05059236
Drug: Darolutamide (BAY1841788, Nubeqa)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg per tablet, oral administration with food
Study: NCT05444530
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Ipilimumab as IV infusion.
Study: NCT05724563
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab 360 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
Study: NCT05724563
Drug: Domvanalimab
Normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domvanalimab 1200 mg IV every 3 weeks until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason.
Study: NCT05030272
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive an 8-week course of transdermal nicotine patches. The first 4 weeks of use will be 21mg/24 hours, followed by 2 weeks of 14mg/24 hours patches, and finally 2 weeks of 7mg/24 hours patches.
Study: NCT05030272
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant enrolled will be given NRT gum (5-10week course) to be taken orally as nicotine cravings arise. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) gum pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.
Study: NCT05030272
Drug: Nicotine Lozenges
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In cases where participants are unable to chew nicotine gum, lozenges will be sent as a replacement of Nicotine gum. Depending on participants' nicotine dependence, they will receive either the 2mg or 4mg (if they smoke within the first 30 minutes of waking) lozenge pieces per package instructions. We will direct subjects to use them for the first weeks following their quit date, using no more than one every 1-2 hours.